2 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
Follow Compass Pathways: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) Psilocybin - Treatment Resistant Depression | Phase 2 | Unknown | Sheppard Pratt Health System | 27 | 2021-03-01 | 2024-08-09 |
| The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. Psilocybin - Treatment Resistant Depression | Phase 2 | Unknown | Sheppard Pratt Health System | 15 | 2021-03-01 | 2022-10-25 |
Depressive Disorder, Treatment-Resistant (2)
Psilocybin (2)
United States (2)
PMID 38055270, PMID 39343309, PMID 39741440, PMID 40499827, PMID 42248535